SCHEMBL5609957

SCHEMBL5609957

O=S(=O)(Nc1cc[c]cc1)c1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.59
NFE2L2 Q16236 1/20 0.59
KMT2A Q03164 2/20 0.55
SNCA P37840 1/20 0.52
ALDH1A1 P00352 3/20 0.51
POLB P06746 2/20 0.51
MEN1 O00255 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
SLC40A1 Q9NP59 3/20 0.50
GLO1 Q04760 1/20 0.50
TSHR P16473 1/20 0.48
GAA P10253 1/20 0.48
NAPRT Q6XQN6 1/20 0.47
MAP2K7 O14733 1/20 0.47
MAP2K4 P45985 1/20 0.47
TP53 P04637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
BRD4 O60885 1/20 0.46
CYP11B1 P15538 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565637 0.85 KEAP1 (0.64) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL784141 0.85 KEAP1 (0.66) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL5609671 0.83 KMT2A (0.54) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL29118864 0.81 KEAP1 (0.65) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL30676966 0.81 KEAP1 (0.65) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL5015931 0.81 KEAP1 (0.68) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL5609530 0.80 NAPRT (0.53) KEAP1NFE2L2KMT2ANAPRT
SCHEMBL194421 0.79 KEAP1 (0.73) KEAP1KMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL5330736 0.77 ALDH1A1 (0.64) KEAP1NFE2L2KMT2ASNCAALDH1A1
SCHEMBL7856929 0.77 KEAP1 (0.63) KEAP1NFE2L2KMT2ASNCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103339132-A Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi YOUAI CO LTD 2013-10-02 CN disclosed
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 EP disclosed
EP-1695716-A2 Medicinal compositions containing diuretics and insulin sensitizers Sankyo Company, Limited (JP) 2006-08-30 EP disclosed
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2005-12-29 US disclosed
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2004-03-18 US disclosed
US-20040006141-A1 Amidocarboxylic acid compounds SANKYO COMPANY, LTD (JP) 2004-01-08 US disclosed
EP-1354602-A1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT Sankyo Company, Limited (JP) 2003-10-22 EP disclosed
EP-0916651-B1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES SANKYO CO (JP) 2003-10-15 EP disclosed
CN-1104413-C Phenylalkylcarboxylic acid derivatives SANKYO CO (JP) 2003-04-02 CN disclosed
CN-1056840-C Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2000-09-27 CN disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
EP-1026149-A1 AMIDOCARBOXYLIC ACID DERIVATIVES Sankyo Company Limited (JP) 2000-08-09 EP disclosed
US-5972959-A Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1999-10-26 US disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP disclosed
US-5780490-A A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS SANKYO COMPANY, LIMITED (JP) 1998-07-14 US disclosed
US-5703096-A ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1997-12-30 US disclosed
CN-1143639-A Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-02-26 CN disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 KEAP1 570/4885NFE2L2 1636/4885KMT2A 4498/4885
US-20040006141-A1 Amidocarboxylic acid compounds NR1H2, AGK, APOL1 KEAP1 1187/4885NFE2L2 919/4885KMT2A 3611/4885
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 KEAP1 570/4885NFE2L2 1636/4885KMT2A 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.